Consistent with the established connections between KRAS and NRF2, it has been demonstrated that restricting glutamine can trigger pro-ferroptosis signals, such as GPX4 suppression, in pancreatic cancer cells with KRAS mutations (Mukhopadhyay et al. 2020). The gene discussed is KRAS; the disease is pancreatic neoplasm.